Class Action Lawsuits Target Financial Misconduct by Marex, aTyr, Cepton, MoonLake
Several companies are facing class action lawsuits due to alleged financial misconduct and misinformation. Investors have until late 2025 to join these legal actions against Marex Group PLC, aTyr Pharma, Cepton, Inc., and MoonLake Immunotherapeutics.
The Marex Group PLC class action alleges that the company sold over-the-counter financial instruments to itself, with inconsistencies in its financial statements. Investors have until December 15, 2025, to petition the court to serve as lead plaintiff in the MoonLake Immunotherapeutics class action, which alleges that the company failed to disclose significant issues with tooling and equipment maintenance in its Tyman Mexico facility.
The aTyr Pharma class action alleges false statements regarding the efficacy of Efzofitimod and its ability to enable patients to completely taper their steroid usage. The company faces multiple class-action lawsuits following the failure of its Phase-3 study, with overly positive statements from company representatives leading to investor misinformation. Investors have until December 8, 2025, to join the legal actions against aTyr Pharma, Marex Group PLC, and Cepton, Inc. The Cepton, Inc. class action alleges that the company engaged in tax fraud and bribery to cover it up.
Bragar Eagel & Squire, P.C., a nationally recognized law firm, is representing investors in these ongoing class actions.
Investors have until December 15 or 8, 2025, depending on the case, to petition the court to serve as lead plaintiff in the class actions against Marex Group PLC, aTyr Pharma, Cepton, Inc., and MoonLake Immunotherapeutics. These lawsuits allege various forms of misconduct, including financial irregularities, misinformation, and fraud. Investors are urged to act promptly to protect their interests.
